CORE ADANIPORTS+0.24% BIRET-0.24% BRIGADE-0.85% DLF-1.17% EMBASSY+1.10% GMRAIRPORT+0.00% GODREJPROP+0.19% IRB+3.46% LODHA-0.98% LT-1.76% MAHLIFE-1.64% MINDSPACE-1.39% NCC-0.64% OBEROIRLTY-0.14% PHOENIXLTD+0.11% PRESTIGE-0.22% SOBHA+0.95% as of 2026-08-26 14:06 UTC

The Annexure

Desk Healthcare Aurobindo Pharma Ltd

Aurobindo Pharma Ltd

BSE 524804 AUROPHARMA INE406A01037
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals NIFTY 500

Filing rhythm · 30 trading days

28 filings · 8 material · busiest 2026-08-05

What it files

Filings

28 in the window

  1. 25 August 2026

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Intimation of Investor/ Analyst meet scheduled on September 1, 2026.

    Company Update / Analyst / Investor Meet View filing →

  2. 25 August 2026

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Intimation of Participation in Investor/ Analyst meet held on September 1-2, 2026 in Hong Kong

    Company Update / Analyst / Investor Meet View filing →

  3. 24 August 2026

    General

    Completion Of US FDA Inspection At Lannett Company LLC, A Wholly Owned Subsidiary Of Aurobindo Pharma USA, Inc.

    Intimation of completion of US FDA inspection at Lannett Company LLC., a wholly owned subsidiary of Aurobindo Pharma, USA Inc.

    Company Update / General View filing →

  4. 21 August 2026

    General

    Completion Of US FDA Inspection At Auro Peptides Ltd, A Subsidiary/Business Arm Of The Company.

    Intimation of completion of US FDA inspection at Auro Peptides Limited, a subsidiary of the Company.

    Company Update / General View filing →

  5. 17 August 2026

    General

    Classification Of US FDA Inspection At Raleigh Plant, North Carolina, Owned By Aurolife Pharma LLC, A Wholly Owned Step-Down Subsidiary Of The Company, As Voluntary Action Indicated (VAI)

    Intimation of classification of US FDA inspection at Raleigh Plant, North Carolina, owned by Aurolife LLF, a wholly owned step down subsidiary of the Company, as Voluntary Actioin Indicated (VAI).

    Company Update / General View filing →

  6. 14 August 2026

    General

    Unit I Of Eugia Pharma Specialities Ltd. Received A Warning Letter From US FDA

    Intimation of receipt of warning letter from US FDA by Unit 1 of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company.

    Company Update / General View filing →

  7. 14 August 2026

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Intimation of participation of officials of the Company in investors / analysts meet to be held on August 19, 2026

    Company Update / Analyst / Investor Meet View filing →

  8. 13 August 2026

    Acquisition

    Acquisition

    Intimation of incorporation of a new wholly owned subsidiary.

    Company Update / Acquisition View filing →

  9. 13 August 2026

    Concall Transcript

    Earnings Call Transcript

    Submission of transcript of the earning call on the unaudited financial results for the quarter ended June 30, 2026.

    Company Update / Earnings Call Transcript View filing →

  10. 7 August 2026

    Newspaper Publication

    Newspaper Publication

    Submission of copies of newspaper advertisements of the financial results of the Company for the first quarter ended June 30, 2026 as published in Business Standard and Nava Telangana on ....

    Company Update / Newspaper Publication View filing →

  11. 7 August 2026

    Newspaper Publication

    Newspaper Publication

    Submission of copies of notice published by the Company on August 7, 2026 in Business Standard and Nava Telangana regarding special window for re-lodgement of transfer requests of physical shares.

    Company Update / Newspaper Publication View filing →

  12. 6 August 2026

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Intimation of participation by the officials of the Company in the Investor/Analyst Meet to be held on August 11 to 13, 2026 in Singapore & Hong Kong

    Company Update / Analyst / Investor Meet View filing →

  13. 5 August 2026

    Board Outcome

    Board Meeting Outcome for Outcome Of The Board Meeting Held On August 5, 2026

    The Board of Directors of the Company at its meeting held today, August 5, 2026, has, inter alia, considered and approved: a) the standalone and consolidated Unaudited Financial Results ....

    Board Meeting / Outcome of Board Meeting View filing →

  14. 5 August 2026

    Investor Presentation

    Investor Presentation

    Submission of investor presentation.

    Company Update / Investor Presentation View filing →

  15. 5 August 2026

    Press Release

    Press Release / Media Release

    Submission of Press Release on financial results of the Company for the first quarter ended June 30, 2026.

    Company Update / Press Release / Media Release View filing →

  16. 5 August 2026

    Restructuring

    Restructuring

    Intimation of proposal of merger of two wholly owned stepdown subsidiaries with a wholly owned subsidiary.

    Company Update / Restructuring View filing →

  17. 4 August 2026

    General

    Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

    Confirmation of dispatch of letter to the shareholders who have not registered their email ids, providing weblink for integrated Annual Report 2025-26.

    Company Update / General View filing →

  18. 4 August 2026

    Newspaper Publication

    Newspaper Publication

    Submission of copies of notice published in newspapers.

    Company Update / Newspaper Publication View filing →

  19. 3 August 2026

    Annual Report

    Reg. 34 (1) Annual Report.

    Submission of Integrated Annual Report 2025-26

    Others / Reg. 34 (1) Annual Report View filing →

  20. 3 August 2026

    AGM / EGM

    Notice Of 39Th Annual General Meeting

    Submission of Notice of 39th Annual General Meeting of the Company to be held August 27, 2026.

    AGM/EGM / AGM View filing →

  21. 3 August 2026

    BRSR

    Business Responsibility and Sustainability Reporting (BRSR)

    Submission of BRSR for FY 2025-26.

    Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →

  22. 30 July 2026

    Newspaper Publication

    Newspaper Publication

    Submission of copies of notice published in newspapers intimating the shareholders that the 39th AGM of the Company will be held on August 27, 2026.

    Company Update / Newspaper Publication View filing →

  23. 29 July 2026

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Intimation of schedule of Earnings Call to be held on August 6, 2026 at 8:30 AM (IST) on Unaudited Financial Results of the Company for the first quarter ended June 30, 2026.

    Company Update / Analyst / Investor Meet View filing →

  24. 29 July 2026

    AGM / EGM

    Intimation Of 39Th Annual General Meeting Of Aurobindo Pharma Limited.

    Intimation of 39th Annual General Meeting of Aurobindo Pharma Limited to be held on August 27, 2026.

    AGM/EGM / AGM View filing →

  25. 27 July 2026

    Board Meeting

    Board Meeting Intimation for Intimation Of Board Meeting.

    Aurobindo Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve Intimation of Board Meeting ....

    Board Meeting / Board Meeting View filing →

  26. 24 July 2026

    Press Release

    Press Release / Media Release

    Submission of press release that is being issued in connection with signing non exclusive voluntary license agreement with MSD.

    Company Update / Press Release / Media Release View filing →

  27. 23 July 2026

    Acquisition

    Acquisition

    Intimation of acquisition of majority ownership control in A1 Biochem Labs (India) Private Limited and A1 Biochem Labs LLC, USA.

    Company Update / Acquisition View filing →

  28. 21 July 2026

    General

    ANVISA Approval For Curateq Biologics' Biosimilars Manufacturing Facility

    Intimation of receipt of ANVISA approval for Biosimilar manufacturing facility of Curateq Biologics Private Limited, a wholly owned subsidiary of the Company.

    Company Update / General View filing →